Physician profile
Andrew Mui
NPI 1992135826
$7,928.30
in general payments reported to CMS, 2019-2025
32 companies · $567 in 2025
The $567 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $849 · 2020: $922 · 2021: $2,302 · 2022: $1,719 · 2023: $1,172 · 2024: $397 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,136.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,114.03 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,069.92 | 2019-2025 | Evenity, Prolia, Prolia |
| Novartis Pharmaceuticals Corporation | $972.83 | 2019-2025 | |
| Lilly USA, LLC | $680.30 | 2019-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $553.07 | 2019-2024 | Spravato, Xarelto |
| Abbvie INC. | $430.66 | 2021-2025 | |
| Gilead Sciences, INC. | $399.20 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $391.97 | 2019-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $344.48 | 2019-2025 | Airsupra |
| Pfizer INC. | $301.97 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $227.75 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Amarin Pharma, INC. | $208.65 | 2020-2021 | |
| Glaxosmithkline, LLC. | $195.86 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $158.12 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.76 | 2019-2025 | Xifaxan |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $124.35 | 2020-2023 | Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $105.06 | 2022 | |
| Sanofi-Aventis U.S. LLC | $79.21 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $62.25 | 2022-2023 | Dupixent |
| Abbott Laboratories | $56.02 | 2019-2023 | Freestyle Libre 3 |
| Radius Health, INC. | $44.49 | 2020-2025 | Tymlos |
| Cranial Technologies, INC | $33.08 | 2024-2025 | Doc Band |
| Axsome Therapeutics, INC. | $32.75 | 2025 | Symbravo |
| Allergan, INC. | $28.74 | 2019-2020 | |
| Abiomed | $28.15 | 2025 | |
| Phathom Pharmaceuticals, INC. | $26.26 | 2024 | Voquezna |
| Biogen, INC. | $22.73 | 2021 | |
| Dexcom, INC. | $18.31 | 2025 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $17.89 | 2023 | |
| Eisai INC. | $16.14 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $14.22 | 2025 | Rexulti |
| Alk-Abello, INC | $13.08 | 2023 | Odactra, Ragwitek, Grastek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Mui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.